Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

Last updated: June 4, 2012
Sponsor: Massachusetts General Hospital
Overall Status: Terminated

Phase

4

Condition

Bipolar Disorder

Bipolar Disorders (Pediatric)

Mood Disorders (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00592358
2007-P-001525
  • Ages 6-17
  • All Genders

Study Summary

This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. Specific hypotheses are as follows:

Hypothesis 1: Bipolar Disorder symptomatology in children and adolescents with DSM-IV Bipolar I, Bipolar II, or Bipolar Spectrum Disorder will be responsive to Invega treatment.

Hypothesis 2: Invega -associated improvement in bipolar disorder symptomatology in children and adolescents will translate into improved functional capacities (neuropsychological, social, and occupational), as well as an increased quality of life throughout treatment.

Hypothesis 2: Invega treatment will be safe and well tolerated as reflected by a low drop out rate and absence of major side effects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male and female outpatients 6-17 years of age (inclusive).

  2. Subjects with the diagnosis of Bipolar or Bipolar Spectrum Disorder and currentlydisplaying manic, hypomanic, or mixed symptoms (with or without psychotic features),by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview.Bipolar Spectrum Disorder (or sub- threshold bipolar disorder) is operationalized ashaving severe mood disturbance, which meets DSM-IV Criteria A for bipolar disorder butdisplay fewer elements in Criteria B (only require 2 items for elation category and 3for irritability).

  3. Subjects must score ≥ 20 on the YMRS.

  4. Subjects and their legal representative must have a level of understanding sufficientto communicate intelligently with the investigator and study coordinator, and tocooperate with all tests and examinations required by the protocol.

  5. Subjects and their legal representative must be considered reliable reporters.

  6. Each subject and his/her authorized legal representative must understand the nature ofthe study. The subject's authorized legal representative must sign an informed consentdocument and the subject must sign an informed assent document (if ≥ 7 years old).

  7. Subject must be able to participate in mandatory blood draws.

  8. Subject must be able to swallow pills.

  9. Subjects with comorbid Oppositional Defiant Disorder (ODD), Conduct Disorder (CD),Obsessive-Compulsive Disorder (OCD), Pervasive Developmental Disorder (PDD), anxietyand depressive disorders will be allowed to participate in the study provided they donot meet for any of the exclusionary criteria.

  10. For concomitant therapy used to treat ADHD, subjects must have been on a stable doseof the medication for 1 month prior to study enrollment. The dose of the ADHD therapywill not change throughout the duration of the study.

Exclusion

Exclusion Criteria:

  1. Investigator and his/her immediate family; defined as the investigator's spouse,parent, child, grandparent, or grandchild.

  2. Serious, unstable illness including hepatic, renal, gastroenterological, respiratory,cardiovascular (including ischemic heart disease), endocrinologic, neurologic,immunologic, or hematologic disease.

  3. Uncorrected hypothyroidism or hyperthyroidism.

  4. Non-febrile seizures without a clear and resolved etiology.

  5. DSM-IV substance (except nicotine or caffeine) dependence within past 6 months.

  6. Judged clinically to be at serious suicidal risk.

  7. Any other concomitant medication with primary central nervous system activity otherthan specified in the Concomitant Medication portion of the protocol.

  8. Current diagnosis of schizophrenia.

  9. Mental retardation (IQ < 75).

  10. Pregnant or nursing females.

  11. Known hypersensitivity to Invega® or similar formulations (paliperidone, risperidone).

  12. A non-responder or history of intolerance to Invega®, after treatment at adequatedoses as determined by the clinician.

  13. Severe allergies or multiple adverse drug reactions.

  14. Subjects with a hematological disorder.

  15. Subjects with diabetes.

Study Design

Total Participants: 17
Study Start date:
November 01, 2007
Estimated Completion Date:
December 31, 2009

Study Description

Invega (paliperidone), a second generation antipsychotic (SGA), is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Invega is approved by the FDA for the treatment of schizophrenia in adults. Initial data suggest a promising role for Invega in the treatment of bipolar disorder with minimal adverse events of weight gain. We propose to study the safety and efficacy of Invega therapy in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum Disorder. The study results will be used to generate hypotheses for a larger, randomized, controlled clinical trial with explicit hypotheses and sufficient statistical power.

The proposed study includes 1) use of a 8-week design to document the response rate, 2) assessment of the impact of Invega on functional capacities (quality of life, psychosocial function) and cognition, and 3) careful assessment of safety and tolerability.

Connect with a study center

  • Massachusetts General Hospital

    Cambridge, Massachusetts 02138
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.